US 12,486,342 B2
Cyclopentadienyl/adamantyl phosphinimine zirconium and hafnium complexes
Xiaoliang Gao, Calgary (CA); Charles Carter, Calgary (CA); P. Scott Chisholm, Calgary (CA); Janelle Smiley-Wiens, Calgary (CA); Darryl Morrison, Calgary (CA); Alva Woo, Calgary (CA); Cheng Fan, Calgary (CA); Chia Yun Chang, Calgary (CA); and Frederick Chiu, Calgary (CA)
Assigned to NOVA CHEMICALS (INTERNATIONAL) S.A., Fribourg (CH)
Appl. No. 17/919,036
Filed by NOVA CHEMICALS (INTERNATIONAL) S.A., Fribourg (CH)
PCT Filed Apr. 16, 2021, PCT No. PCT/IB2021/053165
§ 371(c)(1), (2) Date Oct. 14, 2022,
PCT Pub. No. WO2021/214612, PCT Pub. Date Oct. 28, 2021.
Claims priority of provisional application 63/012,968, filed on Apr. 21, 2020.
Prior Publication US 2023/0235100 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C08F 4/6592 (2006.01); C07F 17/00 (2006.01); C08F 210/16 (2006.01)
CPC C08F 4/6592 (2013.01) [C07F 17/00 (2013.01); C08F 210/16 (2013.01)] 23 Claims
 
1. A complex having the formula (PI)(Cp)ML2, wherein:
I) PI is a phosphinimine ligand defined by the formula:

OG Complex Work Unit Chemistry
where N is a nitrogen atom; P is a phosphorus atom; each R1 is unsubstituted adamantyl, or substituted adamantyl; and R1′ is selected from the group consisting of unsubstituted adamantyl, substituted adamantyl and C1 to C6 hydrocarbyl;
II) Cp is a cyclopentadienyl-type ligand comprising a 5-membered carbon ring having delocalized bonding within the ring and bound to M, which ring is unsubstituted or may be further substituted;
III) each L is an activatable ligand; and
IV) M is zirconium or hafnium.